Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2005

View Archived Issues

Senetek completes Zeatin preclinical studies

Phase II PEAK study begins for Velcade in lung cancer

Calpain: a potential target for the treatment of diabetic vascular complications

Virax advances HIV/AIDS Co-X-Gene programs

Phase III trial studies panitumumab for first-line treatment of colorectal cancer

Phase I study assesses MT-201 with Taxotere for breast cancer treatment

Gilead progresses new fixed-dose combination of Truvada and Sustiva

Encysive restructures agreement with Revotar

Maxim receives milestone payment under agreement with Myriad Genetics

Bentley and Dong Sung sign agreement for intranasal insulin in South Korea

Alzhemed phase III trial recommended to continue

Aloxi receives European approval

Daiichi terminates TZT-1027 licensing agreement with Teikoku Hormone

Dosing under way in phase I/II trial of ImmunoVEX-Trimelan

New phase I trial of TST-10088 in advanced solid tumor patients

NDA for tetrabenazine for chorea associated with Huntington's disease

Novel antiinfective agents disclosed in recent patent literature

Compounds for treatment of Flaviviridae infections reported

New agents claimed for the treatment of lipoprotein disorders, obesity, etc.

Update on atosiban in the management of dysmenorrhea and preterm labor

One-year results of the RIO-Europe study support the use of rimonabant in obesity

Significant protection against HPV infection achieved with Gardasil in young women

CHEC-9 blocks sPLA2 activity in vitro and in vivo / News in Context

Effective post-exposure therapy against West Nile virus in mice

Hayashibara claims novel therapeutic agents for osteoporosis

CR-064 neutralizes procancerous actions of ARP4

Nonpeptide Smac mimetics represent a novel class of anticancer agents

Novel beta-catenin inhibitors delay the growth of colon cancer tumors in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...